Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lanreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 known ✓ | P35346 | 16/20 | 1.00 |
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 1.00 |
| ▸ | SSTR3 | P32745 | 9/20 | 1.00 |
| ▸ | SSTR1 | P30872 | 3/20 | 1.00 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanreotide SCHEMBL29402091 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19472556 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29381700 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29356077 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19962799 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14674691 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29450601 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL21091289 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL22928940 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL28187023 | 0.99 | SSTR5 (0.99) | SSTR5SSTR2SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205245-A1 | LIPOSOMAL ANTICANCER COMPOSITIONS | IRISYS, INC. | 2021-07-08 | — | — | US | disclosed |
| US-11033520-B2 | Liposomal anticancer compositions | IRISYS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200197494-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | AEGIS THERAPEUTICS, LLC | 2020-06-25 | — | — | US | disclosed |
| US-10413594-B2 | Conjugates of somatostatin analogues | PROLYNX LLC (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190269635-A1 | LIPSOMAL ANTICANCER COMPOSITIONS | IRISYS, INC. | 2019-09-05 | — | — | US | disclosed |
| WO-2017212390-A1 | PROCESS FOR LANREOTIDE ACETATE PREPARATION | EMCURE PHARMACEUTICALS LTD, (IN) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017178950-A1 | PROCESS FOR PREPARATION OF LANREOTIDE ACETATE | EMCURE PHARMACEUTICALS LIMITED (IN) | 2017-10-19 | — | — | WO | disclosed |
| US-20160339075-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF SOMATOSTATIN ANALOGS | IPSEN PHARMA S.A.S. (FR) | 2016-11-24 | — | — | US | disclosed |
| US-20160271227-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | PROLYNX LLC (US) | 2016-09-22 | — | — | US | disclosed |
| US-9352012-B2 | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs | IPSEN PHARMA S.A.S. (FR) | 2016-05-31 | — | — | US | disclosed |
| US-20130079282-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF SOMATOSTATIN ANALOGS | IPSEN PHARMA S.A.S. (FR) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269635-A1 | LIPSOMAL ANTICANCER COMPOSITIONS | LIPA, DLST, LIPC | SSTR5 4714/4885SSTR2 4739/4885SSTR3 4742/4885 |
| US-11033520-B2 | Liposomal anticancer compositions | OTC, LIPA, TP53 | SSTR5 4518/4885SSTR2 4665/4885SSTR3 4659/4885 |
| US-20200197494-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | IAPP, NGLY1, VIP | SSTR5 235/4885SSTR2 374/4885SSTR3 195/4885 |
| US-20130079282-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF SOMATOSTATIN ANALOGS | SSTR5, SSTR3, SSTR4 | SSTR5 1/4885SSTR2 4/4885SSTR3 2/4885 |
| US-20210205245-A1 | LIPOSOMAL ANTICANCER COMPOSITIONS | LIPA, PHOSPHO1, MCL1 | SSTR5 4194/4885SSTR2 4562/4885SSTR3 4300/4885 |
| US-20160271227-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | SSTR4, SSTR3, SSTR2 | SSTR5 4/4885SSTR2 3/4885SSTR3 2/4885 |
| US-10413594-B2 | Conjugates of somatostatin analogues | SSTR4, SSTR3, SSTR2 | SSTR5 4/4885SSTR2 3/4885SSTR3 2/4885 |
| US-20160339075-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF SOMATOSTATIN ANALOGS | SSTR5, SSTR4, SSTR3 | SSTR5 1/4885SSTR2 4/4885SSTR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.